个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Specific Gene Co-variation Acts Better Than Number of Concomitant Altered Genes in Predicting EGFR-TKI Efficacy in Non-small-cell Lung Cancer

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Yan-juan Zhu[1,2] * ; Xin Qu[1,2] * ; Dan-dan Zhan[3] ; Hui-hui Chen[3,6] ; Hai-peng Li[3,7] ; Li-rong Liu[1,2] ; Xian Chen[1,2] ; Yi-hong Liu[1,2] ; Yong Li[1,2] ; Jian-ping Bai[1,2] ; Sheng Ye[5] ; Hai-bo Zhang[1,2,4,*1] ;
机构： [1]Department of Oncology, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China [2]Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China [3]Department of Oncology, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China [4]Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou, China [5]Department of Oncology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China [6]Department of Gynecology, Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine, Zhuhai, China [7]Area 7 of Tumor Chemotherapy Department, Central Hospital of Guangdong Nongken, Zhanjiang, China
出处：
DOI： 10.1016/j.cllc.2020.09.003
ISSN：

关键词： Bio-marker Epidermal growth factor receptor tyrosine kinase inhibitors Next-generation sequencing Number of genetic variations Specific genetic alterations

摘要：
Using a 168-gene next-generation sequencing panel, tumor and plasma samples from 48 patients with untreated EGFR-mutant non–small-cell lung cancer were analyzed. Concurrent RB1, PIK3CA, and ERBB2 variants, rather than number of altered genes, indicated poorest progression-free survival after taking epidermal growth factor receptor tyrosine kinase inhibitors. The progression-free survival of patients with ≤ 3 genetic co-variations and altered specific genes were significantly poorer than those with > 3 genetic co-alterations and wild specific genes. © 2020 The Author(s)

基金：
The authors would like to thank all the patients enrolled in this study. The authors also thank Hong-hong Yan for the help in statistical analysis. This study was supported by Guangzhou Municipal Science and Technology Bureau , China (grant number 201604020017 ), the Science and Technology Planning Project of Guangdong Province (grant number 2017B030314166 ), and Guangdong Provincial Hospital of Chinese Medicine (grant number YN2016QL04 ).
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
大类 | 2 区 医学
小类 | 3 区 肿瘤学
最新[2025]版：
大类 | 3 区 医学
小类 | 3 区 肿瘤学
JCR分区：
出版当年[2019]版：
Q2 ONCOLOGY
最新[2023]版：
Q2 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者：
第一作者机构： [1]Department of Oncology, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China [2]Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China
共同第一作者：
通讯作者：
通讯机构： [1]Department of Oncology, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China [2]Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China [4]Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou, China [*1]No. 111, Dade Road, Guangzhou,Guangdong, China, 510120
推荐引用方式(GB/T 7714)：
Yan-juan Zhu,Xin Qu,Dan-dan Zhan,et al.Specific Gene Co-variation Acts Better Than Number of Concomitant Altered Genes in Predicting EGFR-TKI Efficacy in Non-small-cell Lung Cancer[J].CLINICAL LUNG CANCER.2021,22(1):E98-E111.doi:10.1016/j.cllc.2020.09.003.
APA：
Yan-juan Zhu,Xin Qu,Dan-dan Zhan,Hui-hui Chen,Hai-peng Li...&Hai-bo Zhang.(2021).Specific Gene Co-variation Acts Better Than Number of Concomitant Altered Genes in Predicting EGFR-TKI Efficacy in Non-small-cell Lung Cancer.CLINICAL LUNG CANCER,22,(1)
MLA：
Yan-juan Zhu,et al."Specific Gene Co-variation Acts Better Than Number of Concomitant Altered Genes in Predicting EGFR-TKI Efficacy in Non-small-cell Lung Cancer".CLINICAL LUNG CANCER 22..1(2021):E98-E111

相关文献

[1]Characterization of Human Salivary Extracellular RNA by Next-generation Sequencing. [2]Yiqi Chutan Tang Reduces Gefitinib-Induced Drug Resistance in Non-Small-Cell Lung Cancer by Targeting Apoptosis and Autophagy. [3]Characterization of the novel HLA-A*30:154 allele by next-generation sequencing. [4]Next-Generation Sequencing Characterizes the Landscape of Somatic Mutations and Pathways in Metastatic Bile Tract Carcinoma. [5]Pulmonary infection of Schizophyllum commune diagnosed by metagenomic next- generation sequencing: A case report [6]Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology(Open Access) [7]Next-generation HLA sequencing reveals the novel HLA-A*33:244 allele [8]运用二代测序技术确认pcr-ssop法检出的hla罕见等位基因 [9]A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood. [10]The full-length genomic sequence of a novel HLA-C*07 allele, HLA-C*07:63, identified in a Chinese individual.

资源点击量：2020 今日访问量：0 总访问量：646 更新日期：2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持：重庆聚合科技有限公司 地址：广州市越秀区大德路111号